Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Nanobiotix SA (NANO) EUR0.03

Sell:€6.27 Buy:€6.32 Change: €0.08 (1.25%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Change: €0.08 (1.25%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Change: €0.08 (1.25%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. Specifically, NanoXray products may overcome the current limitations of standard of care in local therapy. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Contact details

60 rue de Wattignies
+33 (1) 40260470

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€164.26 million
Shares in issue:
22.71 million
Euronext Paris

Key personnel

  • Laurent Condomine
    Independent Chairman of the Supervisory Board
  • Laurent Levy
    Chairman of the Management Board and Chief Executive Officer
  • Philippe Mauberna
    Member of the Management Board, Chief Financial Officer,
  • Alain Dostie
    Chief Operating Officer
  • Edwina Baskin-Bey
    Member of the Management Board, Medical Director
  • Elsa Borghi
    Member of the Management Board, Product Development & Innovation
  • Bernd Muehlenweg
    Member of the Management Board, Head of Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.